High-dose sequential chemotherapy (HDS) versus PEB chemotherapy as first-line treatment of patients with poor prognosis germ-cell tumors: Mature results of an Italian randomized phase II study

Annals of Oncology

Volumn 26, Issue 1, 2015, Pages 167-172

  Necchi, A ^a   Mariani, L ^b   Di Nicola, M ^a   Lo Vullo, S ^b   Nicolai, N ^c   Giannatempo, P ^a   Raggi, D ^a   Fare E ^a   Magni, M ^a   Piva, L ^c   Matteucci, P ^a   Catanzaro, M ^c   Biasoni, D ^c   Torelli, T ^c   Stagni, S ^c   Bengala, C ^d   Barone, C ^e   Schiavetto, I ^f   Siena, S ^f   Carlo Stella, C ^g,h   Pizzocaro, G ^c   Salvioni, R ^c   M Gianni, A ^a,h   more..

^a Department of Medical Oncology ^*  (Italy)

^b Dept of Neurosci H San Raffaele   (Italy)

^c NATIONAL CANCER INSTITUTE   (Italy)

^d MISERICORDIA HOSPITAL   (Italy)

^e Oncologia Medica ASL TO5 Ospedale di Carmagnola   (Italy)

^f OSPEDALE NIGUARDA CA GRANDA   (Italy)

^g HUMANITAS CLINICAL AND RESEARCH CENTER   (Italy)

^h UNIVERSITY OF MILAN   (Italy)

Author keywords

Germ cell cancer; High dose chemotherapy; Poor prognosis; Testicular neoplasms; Transplantation

Indexed keywords

ALPHA FETOPROTEIN; BLEOMYCIN; CHORIONIC GONADOTROPIN; CISPLATIN; CYCLOPHOSPHAMIDE; ETOPOSIDE; GRANULOCYTE COLONY STIMULATING FACTOR; LACTATE DEHYDROGENASE; TUMOR MARKER; ANTINEOPLASTIC AGENT; CARBOPLATIN; DRUG COMBINATION;

ADULT; ADVANCED CANCER; ARTICLE; AUTOLOGOUS STEM CELL TRANSPLANTATION; BLOOD TOXICITY; CANCER CHEMOTHERAPY; CANCER PROGNOSIS; CANCER SURGERY; CANCER SURVIVAL; CLINICAL EFFECTIVENESS; CONTROLLED STUDY; DRUG DOSE SEQUENCE; DRUG MEGADOSE; FEMALE; FOLLOW UP; GASTROINTESTINAL TOXICITY; GERM CELL TUMOR; HUMAN; INFECTION; LIVER TOXICITY; MAJOR CLINICAL STUDY; MALE; MINIMAL RESIDUAL DISEASE; MULTIPLE CYCLE TREATMENT; NEPHROTOXICITY; NEUROTOXICITY; OVERALL SURVIVAL; PHASE 2 CLINICAL TRIAL; PRIMARY HEALTH CARE; PROGRESSION FREE SURVIVAL; RANDOMIZED CONTROLLED TRIAL; SEPSIS; TREATMENT OUTCOME; TREATMENT RESPONSE; CLINICAL TRIAL; COMPARATIVE STUDY; DISEASE FREE SURVIVAL; DRUG COMBINATION; HEMATOPOIETIC STEM CELL TRANSPLANTATION; MORTALITY; MULTICENTER STUDY; NEOPLASMS, GERM CELL AND EMBRYONAL; TESTICULAR NEOPLASMS; YOUNG ADULT;

ADULT; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BLEOMYCIN; CARBOPLATIN; CISPLATIN; CYCLOPHOSPHAMIDE; DISEASE-FREE SURVIVAL; DRUG COMBINATIONS; ETOPOSIDE; FEMALE; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HUMANS; MALE; NEOPLASMS, GERM CELL AND EMBRYONAL; TESTICULAR NEOPLASMS; YOUNG ADULT;

EID: 85018215507     PISSN: 09237534     EISSN: 15698041     Source Type: Journal    
DOI: 10.1093/annonc/mdu485     Document Type: Article

References (21)

1. International Germ Cell Collaborative Group. International Germ Cell Consensus Classification: a prognostic factor-based staging system for metastatic germ cell cancers. J Clin Oncol 1997; 15: 594-603
2. Williams SD, Birch R, Einhorn LH et al. Treatment of disseminated germ-cell tumors with cisplatin, bleomycin, and either vinblastine or etoposide. N Engl J Med 1987; 316: 1435-1440
3. Nichols CR, Williams SD, Loehrer PJ et al. Randomized study of cisplatin dose intensity in poor-risk germ cell tumors: a Southeastern Cancer Study Group and Southwest Oncology Group protocol. J Clin Oncol 1991; 9: 1163-1172
4. Nichols CR, Catalano PJ, Crawford ED et al. Randomized comparison of cisplatin and etoposide and either bleomycin or ifosfamide in treatment of advanced disseminated germ cell tumors: an Eastern Cooperative Oncology Group, Southwest Oncology Group, and Cancer and Leukemia Group B study. J Clin Oncol 1998; 16: 1287-1293
5. Kaye SB, Mead GM, Fossa SD et al. Intensive induction-sequential chemotherapy with BOP/VIP-B compared with treatment with BEP/EP for poor prognosis metastatic nonseminomatous germ cell tumor: a randomized Medical Research Council/European Organization for the Research and Treatment of Cancer study. J Clin Oncol 1998; 16: 692-701
6. Bower M, Newlands ES, Holden L, Rustin GJ, Begent RH. Treatment of men with metastatic non-seminomatous germ cell tumours with cyclical POMB/ACE chemotherapy. Ann Oncol 1997; 8: 477-483
7. Germa-Lluch JR, Garcia-del-Muro X, Tabernero JM et al. BOMP/EPI intensive alternating chemotherapy for IGCCC poor-prognosis germ cell tumors: the Spanish Germ Cell Cancer Group experience (GG). Ann Oncol 1999; 10: 289-293
8. Motzer RJ, Mazumdar M, Bajorin DF et al. High-dose carboplatin, etoposide, and cyclophosphamide with autologous bone marrow transplantation in first-line therapy for patients with poor-risk germ cell tumors. J Clin Oncol 1997; 15: 2546-2552
9. Schmoll HJ, Kollmannsberger C, Metzner B et al. Long-term results of first-line sequential high-dose etoposide, ifosfamide, and cisplatin chemotherapy plus autologous stem cell support for patients with advanced metastatic germ cell cancer: an extended phase I/II study of the German Testicular Cancer Study Group. J Clin Oncol 2003; 21: 4083-4091
10. Motzer RJ, Mazumdar M, Gulati SC et al. Phase II trial of high-dose carboplatin and etoposide with autologous bone marrow transplantation in first-line therapy for patients with poor-risk germ cell tumors. J Natl Cancer Inst 1993; 85: 1828-1835
11. Motzer RJ, Nichols CR, Margolin KA et al. Phase III randomized trial of conventional-dose chemotherapy with or without high-dose chemotherapy and autologous hematopoietic stem-cell rescue as first-line treatment for patients with poor-prognosis metastatic germ cell tumors. J Clin Oncol 2007; 25: 247-256
12. Droz JP, Kramar A, Biron P et al. Failure of high-dose cyclophosphamide and etoposide combined with double-dose cisplatin and bone marrow support in patients with high-volume metastatic nonseminomatous germ-cell tumours: mature results of a randomised trial. Eur Urol 2007; 51: 739-748
13. Necchi A, Nicolai N, Mariani L et al. Modified cisplatin, etoposide, and ifosfamide (PEI) salvage therapy for male germ cell tumors: long-term efficacy and safety outcomes. Ann Oncol 2013; 24: 2887-2892
14. Cancer Therapy Evaluation Program, Common Terminology Criteria for Adverse Events, version 4.03. NIH. http://ctep.cancer.gov/protocolDevelopment/electronic_ applications/ctc.htm#ctc_40 (20 June 2014, date last accessed)
15. Einhorn LH, Williams SD, Chamness A et al. High-dose chemotherapy and stemcell rescue for metastatic germ-cell tumors. N Engl J Med 2007; 26: 340-348
16. Feldman DR, Sheinfeld J, Bajorin DF et al. TI-CE high-dose chemotherapy for patients with previously treated germ cell tumors: results and prognostic factor analysis. J Clin Oncol 2010; 28: 1706-1713
17. Bokemeyer C, Kollmannsberger C, Meisner A et al. First-line high-dose chemotherapy compared with standard-dose PEB/VIP chemotherapy i patients with advanced germ cell tumors: a multivariate and matched-pair analysis. J Clin Oncol 1999; 17: 3450-3456
18. van Dijk MR, Steyerberg EW, Habbema JD. Survival of non-seminomatous germ cell cancer patients according to the IGCC classification: an update based on meta-analysis. Eur J Cancer 2006; 42: 820-826
19. Farè E, Lo Vullo S, Giannatempo P et al. Clinical outcomes of poor prognosis germ cell tumors (GCT): an analysis of a series from a single referral center. In: European Society for Medical Oncology (ESMO) annual meeting. Madrid, Spain, 26-30 September 2014 (abstract 859P)
20. De Wit R, Skoneczna I, Daugaard G et al. Randomized phase III study comparing paclitaxel-bleomycin, etoposide, and cisplatin (BEP) to standard BEP in intermediate-prognosis germ-cell cancer: intergroup study EORTC 30983. J Clin Oncol 2012; 30: 792-799
21. Fizazi K, Pagliaro LC, Flechon A et al. A phase III trial of personalized chemotherapy based on serum tumor marker decline in poor-prognosis germ-cell tumors: results of GETUG 13. J Clin Oncol 2013: (suppl); abstr LBA4500